• 1
    Pierson RN, III, Tew DN, Konig WK, Dunning JJ, White DJ, Wallwork J. Pig lungs are susceptible to hyperacute rejection by human blood in a working ex vivo heart-lung model. Transplant Proc 1994; 26(3): 1318.
  • 2
    Pierson RN, III, Dunning JJ, Konig WK et al. Mechanisms governing the pace and character of pig heart-lung rejection by human blood. Transplant Proc 1994; 26(4): 2337.
  • 3
    Pierson RN, III, Kasper-Konig W, Tew DN et al. Hyperacute lung rejection in a pig-to-human transplant model: The role of anti-pig antibody and complement. Transplantation 1997; 63(4): 594603.
  • 4
    Macchiarini P, Mazmanian GM, Oriol R et al. Ex vivo lung model of pig-to-human hyperacute xenograft rejection. J Thorac Cardiovasc Surg 1997; 114(3): 315325.
  • 5
    Daggett CW, Yeatman M, Lodge AJ et al. Swine lungs expressing human complement-regulatory proteins are protected against acute pulmonary dysfunction in a human plasma perfusion model. J Thorac Cardiovasc Surg 1997; 113(2): 390398.
  • 6
    Yeatman M, Daggett CW, Parker W et al. Complement-mediated pulmonary xenograft injury: Studies in swine-to-primate orthotopic single lung transplant models. Transplantation 1998; 65(8): 10841093.
  • 7
    Pierson RN, III, Pino-Chavez G, Young VK, Kaspar-Konig W, White DJ, Wallwork J. Expression of human decay accelerating factor may protect pig lung from hyperacute rejection by human blood. J Heart Lung Transplant 1997; 16(2): 231239.
  • 8
    Macchiarini P, Oriol R, Azimzadeh A et al. Evidence of human non-alpha-galactosyl antibodies involved in the hyperacute rejection of pig lungs and their removal by pig organ perfusion. J Thorac Cardiovasc Surg 1998; 116(5): 831843.
  • 9
    D'Apice AJ, Cowan PJ. Profound coagulopathy associated with pig-to-primate xenotransplants: How many transgenes will be required to overcome this new barrier? Transplantation 2000; 70(9): 12731274.
  • 10
    Gaca JG, Lesher A, Aksoy O et al. Disseminated intravascular coagulation in association with pig-to-primate pulmonary xenotransplantation. Transplantation 2002; 73(11): 17171723.
  • 11
    Coller BS, Hirschman RJ, Gralnick HR. Studies on the Factor VIII/von Willebrand factor antigen on human platelets. Thromb Res 1975; 6(6): 469480.
  • 12
    Wagner DD, Marder VJ. Biosynthesis of von Willebrand protein by human endothelial cells: Processing steps and their intracellular localization. J Cell Biol 1984; 99(6): 21232130.
  • 13
    Pareti FI, Fujimora Y, Dent JA, Holland LZ, Zimmerman TS, Ruggeri ZM. Isolation and characterization of a collagen binding domain in human von Willebrand factor. J Biol Chem 1986; 261: 1531015315.
  • 14
    O'Brien JR. Shear induced platelet aggregation. Lancet 1990; 335: 711713.
  • 15
    Howard MA, Firkin BG. Ristocetin: A new tool in the investigation of platelet aggregation. Thromb Diath Haemorrh 1971; 26: 362369.
  • 16
    Inbal A, Loscalo J. Glycocalicin binding to von Willebrand Factor adsorbed onto collagen-coated or polystyrene surfaces. Thromb Res 1989; 56: 347357.
  • 17
    Kroll MH, Harris TS, Moake JL, Handin RI, Schafer AI. Von Willebrand factor binding to platelet GPIb initiates signals for platelet activation. J Clin Invest 1991; 88: 15681573.
  • 18
    Goto S, Salomon DR, Ikeda Y, Ruggeri ZM. Characterization of the unique mechanism mediating the shear-dependent binding of soluble von Willebrand factor to platelets. J Biol Chem 1995; 270(40): 2335223361.
  • 19
    Ruggeri ZM. Structure and function of von Willebrand factor. Thromb Haemost 1999; 82(2): 576584.
  • 20
    Mazzucato M, De Marco L, Pradella P, Masotti A, Pareti FI. Porcine von Willebrand factor binding to human platelet GPIb induces transmembrane calcium influx. Thromb Haemost 1996; 75(4): 655660.
  • 21
    Pareti FI, Mazzucato M, Bottini E, Mannucci PM. Interaction of porcine von Willebrand factor with the platelet glycoproteins Ib and IIb/IIIa complex. Br J Haematol 1992; 82(1): 8186.
  • 22
    Holzknecht ZE, Coombes S, Blocher BA et al. Immune complex formation after xenotransplantation : Evidence of type III as well as type II immune reactions provide clues to pathophysiology. Am J Pathol 2001; 158(2): 627637.
  • 23
    Winkler GC, Cheville NF. Postnatal colonization of porcine lung capillaries by intravascular macrophages: An ultrastructural, morphometric analysis. Microvasc Res 1987; 33(2): 224232.
  • 24
    Staub NC. Pulmonary intravascular macrophages. Annu Rev Physiol 1994; 56: 4767.
  • 25
    Brain JD, Molina RM, DeCamp MM, Warner AE. Pulmonary intravascular macrophages: Their contribution to the mononuclear phagocyte system in 13 species. Am J Physiol 1999; 276(20): L146L154.
  • 26
    Miyamoto K, Schultz E, Heath T, Mitchell MD, Albertine KH, Staub NC. Pulmonary intravascular macrophages and hemodynamic effects of liposomes in sheep. J Appl Physiol 1988; 64(3): 11431152.
  • 27
    Chitko-McKown CG, Chapes SK, Brown RE, Phillips RM, McKown RD, Blecha F. Porcine alveolar and pulmonary intravascular macrophages: Comparison of immune functions. J Leukoc Biol 1991; 50(4): 364372.
  • 28
    Bertram TA, Overby LH, Danilowicz R, Eling TE, Brody AR. Pulmonary intravascular macrophages produce prostaglandins and leukotrienes in vitro. Chest 1988; 93(3 Suppl): 82S84S.
  • 29
    Collins BJ, Blum MG, Parker RE et al. Thromboxane mediates pulmonary hypertension and lung inflammation during hyperacute lung rejection. J Appl Physiol 2001; 90(6): 22572268.
  • 30
    Tector AJ, Fridell JA, Watanabe T et al. Pulmonary injury in recipients of discordant hepatic and renal xenografts in the dog-to-pig model. Xenotransplantation 1998; 5(1): 4449.
  • 31
    Van Rooijen N. The liposome-mediated macrophage ‘suicide’ technique. J Immunol Methods 1989; 124(1): 16.
  • 32
    Van Rooijen N. Liposome-mediated elimination of macrophages. Res Immunol 1992; 143(2): 215219.
  • 33
    Sone Y, Nicolaysen A, Staub NC. Effect of particles on sheep lung hemodynamics parallels depletion and recovery of intravascular macrophages. J Appl Physiol 1997; 83(5): 14991507.
  • 34
    Sone Y, Serikov KB, Staub NC. Intravascular macrophage depletion attenuates endotoxin in lung injury in anesthetized sheep. J Appl Physiol 1999; 87(4): 13541359.
  • 35
    Cantu IIIE, Gaca JG, Palestrant D et al. Depletion of Pulmonary Intravascular Macrophages Prevents Hyperacute Pulmonary Xenograft Dysfunction. Transplantation 2006; 81(8): 11571164.
  • 36
    Gaca JG, Palestrant D, Lukes DJ, Olausson M, Parker W, Davis RD, Jr. Prevention of acute lung injury in swine: Depletion of pulmonary intravascular macrophages using liposomal clodronate. J Surg Res 2003; 112(1): 1925.
  • 37
    Diamond LE, Byrne GW, Schwarz A, Davis TA, Adams DH, Logan JS. Analysis of the control of the anti-gal immune response in a non-human primate by galactose alpha1-3 galactose trisaccharide-polyethylene glycol conjugate. Transplantation 2002; 73(11): 17801787.
  • 38
    Gonzalez-Stawinski GV, Daggett CW, Lau CL et al. Non-anti-Gal alpha 1-3 Gal antibody mechanisms are sufficient to cause hyperacute lung dysfunction in pulmonary xenotransplantation. J Am Coll Surg 2002; 194(6): 765773.
  • 39
    Platt JL, Turman MA, Noreen RJ, Fischel RJ, Bolman RM, Bach FH. An ELISA assay for xenoreactive natural antibodies. Transplantation 1990; 49: 10001001.
  • 40
    Esmon C. The regulation of natural anticoagulant pathways. Science 1987; 235: 1348.
  • 41
    Schleef RR, Loskutoff DJ. Fibrinolytic system of vascular endothelial cells. Role of plasminogen activator inhibitors. Haemostasis 1988; 18(4–6): 328341.
  • 42
    Lau CL, Daggett WC, Yeatman MF et al. The role of antibodies in dysfunction of pig-to-baboon pulmonary transplants. J Thorac Cardiovasc Surg 2000; 120(1): 2938.
  • 43
    Rabinovici R, Yeh CG, Hillegass LM et al. Role of complement in endotoxin/platelet-activating factor-induced lung injury. J Immunol 1992; 149(5): 17441750.
  • 44
    Del Conde I, Cruz MA, Zhang H, Lopez JA, Afshar-Kharghan V. Platelet activation leads to activation and propagation of the complement system. J Exp Med 2005; 201(6): 871879.
  • 45
    Cunningham MA, Romas P, Hutchinson P, Holdsworth SR, Tipping PG. Tissue factor and factor VIIa receptor/ligand interactions induce proinflammatory effects in macrophages. Blood 1999; 94(10): 34133420.
  • 46
    Yan SF, Zou YS, Gao Y et al. Tissue factor transcription driven by Egr-1 is a critical mechanism of murine pulmonary fibrin deposition in hypoxia. Proc Natl Acad Sci U S A 1998; 95: 82988303.
  • 47
    Lawson CA, Yan SD, Yan SF et al. Monocytes and tissue factor promote throbosis in a murine model of oxygen deprivation. J Clin Invest 1997; 90(7): 17291738.
  • 48
    Tracy PB, Allen DH, Worfolk LA, Lawler RR. Monocyte/macrophage regulation of coagulant events. Haemostasis 1996; 26(Suppl 1): 611.
  • 49
    Compeau CG, Ma J, DeCampos KN et al. In situ ischemia and hypoxia enhance alveolar macrophage tissue factor expression. Am J Respir Cell Mol Biol 1994; 11(4): 446455.
  • 50
    Taylor FB, Jr., Chang A, Ruf W et al. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock 1991; 33(3): 127134.
  • 51
    Salom RN, Maguire JA, Hancock WW. Endothelial activation and cytokine expression in human acute cardiac allograft rejection. Pathology 1998; 30(1): 2429.
  • 52
    Furumoto T, Fujii S, Saito N, Mikami T, Kitabatake A. Relationships between brachial artery flow mediated dilation and carotid artery intima-media thickness in patients with suspected coronary artery disease. Jpn Heart J 2002; 43(2): 117125.
  • 53
    Bogdanov VY, Balasubramanian V, Hathcock J, Vele O, Lieb M, Nemerson Y. Alternatively spliced human tissue factor: A circulating, soluble, thrombogenic protein. Nat Med 2003; 9(4): 458462.
  • 54
    Szotowski B, Antoniak S, Poller W, Schultheiss HP, Rauch U. Procoagulant soluble tissue factor is released from endothelial cells in response to inflammatory cytokines. Circ Res 2005; 96(12): 12331239.
  • 55
    Platt JL, Vercellotti GM, Lindman BJ, Oegema TR Jr., Bach FH, Dalmasso AP. Release of heparan sulfate from endothelial cells. Implications for pathogenesis of hyperacute rejection. J Exp Med 1990; 171(4): 13631368.
  • 56
    Moore KL, Esmon CT, Esmon NL. Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture. Blood 1989; 73(1): 159165.
  • 57
    Robson SC, Kaczmarek E, Siegel JB et al. Loss of ATP diphosphohydrolase activity with endothelial cell activation. J Exp Med 1997; 185(1): 153163.
  • 58
    Ikeda K, Nagasawa K, Horiuchi T, Tsuru T, Nishizaka H, Niho Y. C5a induces tissue factor activity on endothelial cells. Thromb Haemost 1997; 77(2): 394398.
  • 59
    Moore KL, Andreoli SP, Esmon NL, Esmon CT, Bang NU. Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. J Clin Invest 1987; 79(1): 124-130.
  • 60
    Lawson JH, Platt JL. Molecular barriers to xenotransplantation. Transplantation 1996; 62(3): 303310.
  • 61
    Siegel JB, Grey ST, Lesnikoski BA et al. Xenogeneic endothelial cells activate human prothrombin. Transplantation 1997; 64(6): 888896.
  • 62
    Sculte am Esch J 2nd, Robson SC et al. O-linked glycosylation and functional incompatibility of porcine von Willebrand factor for human platelet GPIb receptors. Xenotransplantation 2005; 12: 3037.